Clinical trial
Diagnostic and Prognostic Role of FENDRR and CRNDE With DUSP1 and DMBT1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma
NCT07906795 is registered in ClinicalTrials.gov with Amina Fouad Farag as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Diagnostic and Prognostic Role of FENDRR and CRNDE With DUSP1 and DMBT1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma
- Lead sponsor
- Amina Fouad Farag
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 26, 2021
- Completion date
- August 29, 2025
- Enrollment
- 62 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
oral leukoplakia (ol), oral squamous cell carcinoma (oscc)
Arms
As registered; 3 arms.
-
OSCC
Oral squamous cell carinoma
-
OL
Oral leukoplakia
-
Control
Control
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Diagnostic potential of FENDRR, CRNDE, DUSP1 and DMBT1
Expression of lncRNA-FENDRR and lncRNA-CRNDE (relative expression, 2\^-ΔΔCt, by real-time RT-PCR) and tissue levels of DUSP1 (pg/mg protein) and DMBT1 (ng/mg protein, by ELISA) are measured in each tissue specimen. Diagnostic accuracy is assessed with receiver operating characteristic (ROC) curve analysis: area under the curve (AUC) with 95% confidence interval, and sensitivity and specificity, for oral leukoplakia versus controls, oral squamous cell carcinoma versus controls, and oral squamous cell carcinoma versus oral leukoplakia. Accuracy is compared with PI3K, AKT, mTOR, ERK2 and MMP9 measured in the same specimens.
Lead sponsor's other trials
Amina Fouad Farag, most recent start first.
Similar trials
Same condition (Leukoplakia, Oral) and phase, most recent start first.
+14 more trials See the condition page